Repurpose
Use an existing drug for a new indication.
Smart Drug Development Technology
LADR combines proven scientific principles with a focused development strategy to accelerate improved therapies from known drug starting points.
LADR — Ligand-Assisted Drug Remodeling Creates Upgraded Versions of Many Proven and Approved Medicines.
LADR is a covalent prodrug remodeling approach designed to improve PK, tolerability, solubility, and IP position across multiple scaffold classes.
*Relative to de novo development.

A comprehensive approach to improving drug products with maximum flexibility.
Use an existing drug for a new indication.
Create better dosing or pediatric formulations to improve tolerance and efficacy.
Modify a drug to overcome barriers such as solubility so it works better, including changing route of dosing.
Revive assets that were failing due to absorption or tolerability limitations through chemical modification.
Starting with drug substances already approved for human use, LADR applies a modifying agent from a curated library to create an improved, patentable drug. LADR is a chemical modification approach, not a formulation, and does not trigger a 505(b)(1) path.
Not a formulation change, but chemical modification designed to create improved molecular entities.
Creates new, patentable New Chemical Entities with a differentiated development path.
The platform is designed for speed, cost discipline, and risk reduction.
Develop approximately 4x faster as compared to de novo drug development.
~5% of cost as compared to de novo drug development.
Higher probability of success as compared to de novo drug development.
Chemical modification creates patentable New Chemical Entities while avoiding the 10-12 year, $1-3B 505(b)(1) path.
Join Ladrion Therapeutics in advancing affordable therapies through smarter drug development.